Literature DB >> 6296836

Purified Epstein-Barr virus Mr 340,000 glycoprotein induces potent virus-neutralizing antibodies when incorporated in liposomes.

J R North, A J Morgan, J L Thompson, M A Epstein.   

Abstract

The purified Mr 340,000 glycoprotein component of Epstein-Barr (EB) virus-induced membrane antigen complex incorporated into liposomes was shown to be a potent immunogen in mice. High-titer antisera were induced that (i) are specific for membrane antigen components without absorption, (ii) bind the antigens induced by three different EB virus isolates, and (iii) neutralize the ability of the virus to transform fetal cord blood lymphocytes in vitro. The development of this immunogenic form of purified antigen provides an important step towards a potential subunit vaccine against Epstein-Barr virus infection.

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 6296836      PMCID： PMC347368          DOI： 10.1073/pnas.79.23.7504

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN： 0027-8424            Impact factor:   11.205


  34 in total

1.  Hepatitis B surface antigen-containing liposomes enhance humoral and cell-mediated immunity to the antigen.

Authors:  E K Manesis; C H Cameron; G Gregoriadis
Journal:  FEBS Lett       Date:  1979-06-01       Impact factor: 4.124

2.  Biological and biochemical observations on isolates of EB virus from the malignant epithelial cells of two nasopharyngeal carcinomas.

Authors:  D H Crawford; M A Epstein; G W Bornkamm; B G Achong; S Finerty; J L Thompson
Journal:  Int J Cancer       Date:  1979-09-15       Impact factor: 7.396

3.  Comparison of EBV neutralization tests based on abortive infection or transformation of lymphoid cells and their relation to membrane reactive antibodies (anti-MA).

Authors:  A de Schryver; G Klein; J Hewetson; G Rocchi; W Henle; G Henle; D J Moss; J H Pope
Journal:  Int J Cancer       Date:  1974-03-15       Impact factor: 7.396

4.  Epstein-Barr virus: transformation, cytopathic changes, and viral antigens in squirrel monkey and marmoset leukocytes.

Authors:  G Miller; T Shope; H Lisco; D Stitt; M Lipman
Journal:  Proc Natl Acad Sci U S A       Date:  1972-02       Impact factor: 11.205

5.  A film detection method for tritium-labelled proteins and nucleic acids in polyacrylamide gels.

Authors:  W M Bonner; R A Laskey
Journal:  Eur J Biochem       Date:  1974-07-01

6.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

7.  Establishment of cell lines from Australian leukaemic patients: presence of a herpes-like virus.

Authors:  J H Pope
Journal:  Aust J Exp Biol Med Sci       Date:  1968-10

8.  Biochemical characterization of Epstein-Barr virus membrane antigen associated glycoproteins.

Authors:  B C Strnad; T Schuster; R Klein; R H Neubauer
Journal:  Biochem Biophys Res Commun       Date:  1981-02-27       Impact factor: 3.575

9.  Monoclonal antibodies against the major glycoprotein (gp350/220) of Epstein-Barr virus neutralize infectivity.

Authors:  D A Thorley-Lawson; K Geilinger
Journal:  Proc Natl Acad Sci U S A       Date:  1980-09       Impact factor: 11.205

10.  Correlation between Epstein-Barr virus membrane antigen and three large cell surface glycoproteins.

Authors:  B C Strnad; R H Neubauer; H Rabin; R A Mazur
Journal:  J Virol       Date:  1979-12       Impact factor: 5.103
View more
  13 in total

1.  Mapping of B-cell epitopes on the polypeptide chain of the Epstein-Barr virus major envelope glycoprotein and candidate vaccine molecule gp340.

Authors:  R J Pither; C X Zhang; C Shiels; J Tarlton; S Finerty; A J Morgan
Journal:  J Virol       Date:  1992-02       Impact factor: 5.103

Review 2.  Control of viral disease: the development of Epstein-Barr virus vaccines.

Authors:  A J Morgan
Journal:  Springer Semin Immunopathol       Date:  1991

Review 3.  Human herpesviruses: a consideration of the latent state.

Authors:  J G Stevens
Journal:  Microbiol Rev       Date:  1989-09

4.  Not all potently neutralizing, vaccine-induced antibodies to Epstein-Barr virus ensure protection of susceptible experimental animals.

Authors:  M A Epstein; B J Randle; S Finerty; J K Kirkwood
Journal:  Clin Exp Immunol       Date:  1986-03       Impact factor: 4.330

5.  Preparation of liposomes via detergent removal from mixed micelles by dilution. The effect of bilayer composition and process parameters on liposome characteristics.

Authors:  W Jiskoot; T Teerlink; E C Beuvery; D J Crommelin
Journal:  Pharm Weekbl Sci       Date:  1986-10-17

6.  The effect of liposomal charge on the neutralizing antibody response against inactivated encephalomyocarditis and Semliki Forest viruses.

Authors:  C A Kraaijeveld; M Schilham; J Jansen; B Benaissa-Trouw; M Harmsen; A J van Houte; H Snippe
Journal:  Clin Exp Immunol       Date:  1984-06       Impact factor: 4.330

7.  A multigene family encodes the human cytomegalovirus glycoprotein complex gcII (gp47-52 complex).

Authors:  D R Gretch; B Kari; R C Gehrz; M F Stinski
Journal:  J Virol       Date:  1988-06       Impact factor: 5.103

Review 8.  Clinical consequences of Epstein-Barr virus infection and possible control by an anti-viral vaccine.

Authors:  M A Epstein; A J Morgan
Journal:  Clin Exp Immunol       Date:  1983-08       Impact factor: 4.330

9.  Characterization of monoclonal antibodies reactive to several biochemically distinct human cytomegalovirus glycoprotein complexes.

Authors:  B Kari; N Lussenhop; R Goertz; M Wabuke-Bunoti; R Radeke; R Gehrz
Journal:  J Virol       Date:  1986-11       Impact factor: 5.103

10.  Recombinant vaccinia virus induces neutralising antibodies in rabbits against Epstein-Barr virus membrane antigen gp340.

Authors:  M Mackett; J R Arrand
Journal:  EMBO J       Date:  1985-12-01       Impact factor: 11.598
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.